Plain-English translation of NCT06452654 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Diabetes Mellitus, Type 1 research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This is a prevention study for infants who have a higher genetic risk of developing type 1 diabetes. Researchers want to find out whether giving the Comirnaty COVID-19 vaccine early in life might help prevent type 1 diabetes from developing. Half of the children will receive the vaccine and half will receive a placebo (a salt water injection that looks the same but has no medicine).
Type 1 diabetes is an autoimmune disease where the body's immune system attacks cells in the pancreas. Some research suggests that viral infections might trigger this process in children who are genetically prone to it. Scientists want to test whether protecting infants against COVID-19 with a vaccine might reduce their risk of developing type 1 diabetes.
You likely qualify if…
You likely don't qualify if…
Your baby would receive three injections starting at 6 months old, spaced 3 to 8 weeks apart. You would bring your child to clinic visits for these injections and follow-up monitoring. The study will track your child over time to see whether they develop signs of diabetes or related autoimmune conditions. You won't know whether your child is receiving the vaccine or placebo — that's randomly decided.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Austria
Belgium
Germany